Cornerstone Therapeutics has signed an agreement to acquire exclusive US marketing rights to Pertzye (pancrelipase) from Digestive Care (DCI). Pertzye, the pancreatic enzyme product, is indicated for the treatment of exocrine pancreatic ...
Tags: Cornerstone, Digestive Care
US-based Cornerstone Therapeutics has entered into an agreement to acquire the US marketing rights to Chiesi Farmaceutici's BETHKIS (Tobramycin Inhalation Solution), designed for the treatment of cystic fibrosis patients with Pseudomonas ...
Tags: US-based Cornerstone Therapeutics, Chiesi Farmaceutici's BETHKIS
Cornerstone Therapeutics has acquired a privately-held specialty pharmaceutical company focused on the acute-care hospital setting, EKR Therapeutics. As part of the merger, Cornerstone will assume the responsibility to market and promote ...
Tags: Cornerstone Therapeutics
Cornerstone Therapeutics, a specialty pharmaceutical company, has received FDA approval for its abbreviated new drug application (ANDA) for a generic Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release suspension ...
Tags: FDA approval, pharmaceutical product, generic antitussive product